Long-term follow up of autologous serum treatment for recurrent corneal erosions

Clin Exp Ophthalmol. 2010 Oct;38(7):683-7. doi: 10.1111/j.1442-9071.2010.02304.x. Epub 2010 Jul 9.


Purpose: The aim of the study was to evaluate long-term results of autologous serum treatment for recurrent corneal erosions.

Methods: In this prospective single-centre study, 33 eyes of 33 patients (21 male and 12 female) were treated with autologous serum eye drops for recurrent corneal erosions. Mean age of the patients was 49.3 ± 9.8 standard deviation (range 24-73) years. All subjects had failed to respond to other treatments. Autologous serum drops were administered for a 6-month period: six times daily for the first 3 months and four times daily for the remaining 3 months. Detailed informed consent was obtained from the entire patient group before the study.

Results: The mean follow-up period was 30 ± 6.3 standard deviation (range 12-48) months. None of the patients experienced a recurrence while under treatment. Twenty-eight patients (85%) had complete healing of erosions with no relapses of the disease over the whole follow-up period. Five patients (15%) presented a single recurrence 3-12 months after the end of the treatment. No sight-threatening complications were reported over the follow up. There was no statistically significant difference in the best spectacle-corrected visual acuity values (t(stat) = 2.1, F = 0.096, degree of freedom = 40,166, P < 0.41) or in the intraocular pressure measurements (P < 0.38) between the pre- and post-treatment patient groups.

Conclusions: Autologous serum drops proved to be a safe and efficient treatment modality for patients with recurrent corneal erosion syndrome as observed through a long-term follow up.

MeSH terms

  • Adult
  • Aged
  • Blood Proteins / administration & dosage*
  • Corneal Diseases / blood*
  • Corneal Diseases / physiopathology
  • Corneal Diseases / therapy*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Ophthalmic Solutions
  • Recurrence
  • Serum
  • Treatment Outcome
  • Visual Acuity
  • Young Adult


  • Blood Proteins
  • Ophthalmic Solutions